Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $689.9 million.

  • Catalyst Pharmaceuticals' Cash & Equivalents rose 55.97% to $689.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $689.9 million, marking a year-over-year increase of 55.97%. This contributed to the annual value of $517.6 million for FY2024, which is 276.03% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Cash & Equivalents is $689.9 million, which was up 5.68% from $652.8 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Cash & Equivalents ranged from a high of $689.9 million in Q3 2025 and a low of $121.0 million during Q3 2023.
  • For the 3-year period, Catalyst Pharmaceuticals' Cash & Equivalents averaged around $377.7 million, with its median value being $375.7 million (2024).
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Cash & Equivalents crashed by 53.87% in 2023, and later soared by 276.03% in 2024.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Cash & Equivalents stood at $171.4 million in 2021, then skyrocketed by 74.05% to $298.4 million in 2022, then plummeted by 53.87% to $137.6 million in 2023, then surged by 276.03% to $517.6 million in 2024, then soared by 55.97% to $689.9 million in 2025.
  • Its last three reported values are $689.9 million in Q3 2025, $652.8 million for Q2 2025, and $580.7 million during Q1 2025.